Drugs / Gimatecan
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT04029909 | Jul → Dec 2019 | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
| Phase 1 | NCT00493571 | Aug 2007 → May 2014 | myelodysplastic syndrome | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00487058 | May 2007 → Jun 2008 | cancer | Novartis | Completed | No outcome recorded |
| Phase 1 | NCT00441610 | Jan 2007 → Sep 2009 | cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00410358 | Jun 2006 → Feb 2008 | neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00420485 | Mar 2006 → Nov 2010 | cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00033202 | Mar 2002 → Feb 2005 | cancer | Sigma-Tau Research, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00087061 | May 2004 → Jun 2005 | central nervous system neoplasm | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00032903 | Mar 2002 → Oct 2005 | malignant glioma | Sigma-Tau Research, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04846842 | Jul 2021 → Jul 2022 | fallopian tube cancer, malignant epithelial tumor of ovary, peritoneum cancer | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
| Phase 2 | NCT04571489 | Dec 2020 → Dec 2021 | malignant pancreatic neoplasm | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
| Phase 2 | NCT04501029 | Oct 2020 → Oct 2022 | small cell lung carcinoma | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gimatecan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04501029 ↗ |
| Known as | LBQ707 | “A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice per Week to Japanese Patients With Advanced Solid Tumors” NCT00487058 ↗ |
| Known as | ST 1481 | “A Phase I Clinical Study of Gimatecan (ST 1481) in Patients With Platinum-resistant or Sensitive Relapsing/Refractory Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer...” NCT04029909 ↗ |
| Action | Inhibit | “DNA topoisomerase I inhibitor” CHEMBL113051 ↗1“Topoisomerase I inhibitor” NCT00032903 ↗ |
| Modality | Small molecule | — CHEMBL113051 ↗ |
| Route | Oral | “given as a capsule, rather than by intravenous injection” NCT00032903 ↗ |
| Target | TOP1 | “DNA topoisomerase I inhibitor” CHEMBL113051 ↗ |